TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company developing T cell receptor (TCR)-engineered T cell therapies for cancer treatment, announced the acceptance of three abstracts for poster presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting. The event will be held from November 6-10 in Houston, TX and virtually.
The presentations include:
- Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
- Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
- Development of a Target Agnostic Platform to Assess the Reactivity of TCR-T Therapies to Primary Human Tissues
All presentations will take place in the Exhibit Halls AB at the George R. Brown Convention Center. The presentation materials will be available on TScan's website after the event concludes.
TScan Therapeutics, Inc. (Nasdaq: TCRX), una società biotecnologica in fase clinica che sviluppa terapie con cellule T ingegnerizzate (TCR) per il trattamento del cancro, ha annunciato l'accettazione di tre abstract per presentazioni in formato poster al 39° Congresso Annuale della Society for Immunotherapy of Cancer (SITC). L'evento si terrà dal 6 al 10 novembre a Houston, TX e virtualmente.
Le presentazioni includono:
- Scoperta di un candidato terapeutico TCR-T specifico per MAGE-A4 per il trattamento multiplo dei tumori solidi
- Modelli preclinici per T-Plex, una terapia TCR-T multiplex personalizzata che affronta l'eterogeneità degli antigeni intra-tumorali e HLA
- Sviluppo di una piattaforma agnostica all'antigene per valutare la reattività delle terapie TCR-T su tessuti umani primari
Tutte le presentazioni si svolgeranno nelle Sale Espositive AB presso il George R. Brown Convention Center. I materiali delle presentazioni saranno disponibili sul sito web di TScan dopo la conclusione dell'evento.
TScan Therapeutics, Inc. (Nasdaq: TCRX), una empresa biotecnológica en fase clínica que desarrolla terapias de células T (TCR) modificadas para el tratamiento del cáncer, anunció la aceptación de tres resúmenes para presentación de póster en el 39.º Congreso Anual de la Society for Immunotherapy of Cancer (SITC). El evento se llevará a cabo del 6 al 10 de noviembre en Houston, TX y de manera virtual.
Las presentaciones incluyen:
- Descubrimiento de un candidato a terapia TCR-T específico para MAGE-A4 para el tratamiento múltiple de tumores sólidos
- Modelos preclínicos para T-Plex, una terapia TCR-T multiplex personalizada que aborda la heterogeneidad de antígenos intra-tumorales y HLA
- Desarrollo de una plataforma agnóstica a antígenos para evaluar la reactividad de las terapias TCR-T en tejidos humanos primarios
Todas las presentaciones se llevarán a cabo en las Salas de Exhibición AB en el Centro de Convenciones George R. Brown. Los materiales de presentación estarán disponibles en el sitio web de TScan después de que concluye el evento.
TScan Therapeutics, Inc. (Nasdaq: TCRX)는 암 치료를 위한 T세포 수용체(TCR) 엔지니어링 T세포 치료제를 개발하는 임상 단계 생명공학 회사로, 포스터 발표를 위한 세 개의 초록이 수락되었다고 발표했다. 암 면역 치료 학회(SITC) 제39회 연례 회의는 11월 6일부터 10일까지 휴스턴, TX에서 오프라인 및 온라인으로 개최될 예정이다.
발표 내용은 다음과 같다:
- 고형 종양의 다중 치료를 위한 MAGE-A4 특이적 TCR-T 치료 후보 발견
- 내종양 항원 및 HLA 이질성을 다루는 맞춤형 다중 TCR-T 세포 치료제인 T-Plex에 대한 전임상 모델
- 1차 인간 조직에 대한 TCR-T 치료제의 반응성을 평가하기 위한 표적 항원 비의존적 플랫폼 개발
모든 발표는 George R. Brown Convention Center의 전시 홀 AB에서 진행된다. 발표 자료는 이벤트 종료 후 TScan 웹사이트에서 확인할 수 있다.
TScan Therapeutics, Inc. (Nasdaq: TCRX), une entreprise biopharmaceutique en phase clinique qui développe des thérapies à base de cellules T (TCR) modifiées pour le traitement du cancer, a annoncé l'acceptation de trois résumés pour présentation sous forme de poster lors de la 39e Réunion Annuelle de la Society for Immunotherapy of Cancer (SITC). L'événement se tiendra du 6 au 10 novembre à Houston, TX et virtuellement.
Les présentations comprennent :
- Découverte d'un candidat thérapeutique TCR-T spécifique à MAGE-A4 pour le traitement multiplex des tumeurs solides
- Modèles précliniques pour T-Plex, une thérapie TCR-T multiplex personnalisée visant l'hétérogénéité des antigènes intra-tumoraux et HLA
- Développement d'une plateforme agnostique aux antigènes pour évaluer la réactivité des thérapies TCR-T aux tissus humains primaires
Toutes les présentations auront lieu dans les salles d'exposition AB au George R. Brown Convention Center. Les matériaux de présentation seront disponibles sur le site Web de TScan après la conclusion de l'événement.
TScan Therapeutics, Inc. (Nasdaq: TCRX), ein biopharmazeutisches Unternehmen in der klinischen Phase, das T-Zell-Rezeptor (TCR)-ingenieurierte T-Zell-Therapien zur Behandlung von Krebs entwickelt, gab die Annahme von drei Abstracts für Posterpräsentationen auf dem 39. Jahresmeeting der Society for Immunotherapy of Cancer (SITC) bekannt. Die Veranstaltung findet vom 6. bis 10. November in Houston, TX und virtuell statt.
Die Präsentationen umfassen:
- Entdeckung eines MAGE-A4-spezifischen TCR-T Therapie-Kandidaten für die Multiplexbehandlung von soliden Tumoren
- Präklinische Modelle für T-Plex, eine maßgeschneiderte multiplexe TCR-T Zelltherapie zur Ansprache intra-tumoraler Antigen- und HLA-Heterogenität
- Entwicklung einer zielagnostischen Plattform zur Bewertung der Reaktivität von TCR-T Therapien auf primäre menschliche Gewebe
Alle Präsentationen finden in den Ausstellungsräumen AB im George R. Brown Convention Center statt. Die Präsentationsmaterialien sind nach Abschluss der Veranstaltung auf der Website von TScan verfügbar.
- None.
- None.
WALTHAM, Mass., Oct. 04, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of three abstracts for poster presentation at the upcoming Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held November 6 – 10 in Houston, TX and virtually.
Poster Presentation Details:
Title: Discovery of a MAGE-A4-specific TCR-T Therapy Candidate for Multiplex Treatment of Solid Tumors
Authors: Rutuja Kulkarni, Akshat Sharma, Vivin Karthik, Kenneth L Jahan, Rakshi Bala, Nicolas Gaspar, Amanda Kordosky, Daniel C Pollacksmith, Alok Das Mahopatra, Maytal Bowman, Drashti Shah, Victor Ospina, Sanket Shah, Skyler Martinez, Ryan E Kritzer, Jayanth Jawahar, Hana Husic, Shoshana Bloom, Emily Miga, Rachel Lent, Chandan K Pavuluri, Carolyn Hardy, Abigail Dooley, Alex Cristofaro, Zhonghua Zhu, Livio Dukaj, Antoine Boudot, Kimberly M Cirelli, Mollie M Jurewicz, Cagan Gurer
Abstract Number: 375
Session Date/Time: Friday, November 8; 9:00 a.m. - 7:00 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center
Title: Preclinical Models for T-Plex, a Customized Multiplexed TCR-T Cell Therapy Addressing Intra-Tumor Antigen and HLA Heterogeneity
Authors: Maytal Bowman, Amanda Kordosky, Daniel Pollacksmith, Alok Das Mohapatra, Debanjan Goswamy, Victor Ospina, Sanket Revadkar, Shubhangi Kamalia, Skyler Martinez, Gaenna Rogers, Teagan Parsons, Dalena Nguyen, Jenny Tadros, Ira Jain, Alexander Cristofaro, Jenna LaBelle, Ribhu Nayar, Nancy Nabilsi, Antoine Boudot
Abstract Number: 359
Session Date/Time: Friday, November 8; 9:00 a.m. - 7:00 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center
Title: Development of a Target Agnostic Platform to Assess the Reactivity of T Cell Receptor (TCR)-Engineered T Cell (TCR-T) Therapies to Primary Human Tissues
Authors: Sveta Padmanabhan, Shubhangi Kamalia, Drashti Shah, Shazad A Khokhar, Sadie Lee, Daniel C Pollacksmith, Kimberly M Cirelli, Vivin Karthik, Kenneth Jahan, Jenny Tadros, Teagan Parsons, Nancy Nabilsi, Andrew Ferretti, Dalena Nguyen, Livio Dukaj, Jin He, Ryan E Kritzer, Emily Miga, Alexander Cristofaro, Chandan K Pavuluri, Elisaveta Todorova, Tyler M Sinacola, Savannah G Szemethy, Kyra N Sur, Vandana Keskar, Carolyn Hardy, Hsin-Ho Huang, Zhonghua Zhu, Antoine J Boudot, Sonal Jangalwe, Ribhu Nayar, Gavin MacBeath
Abstract Number: 384
Session Date/Time: Saturday, November 9; 9:00 a.m. - 8:30 p.m. Central Time
Location: Exhibit Halls AB – George R. Brown Convention Center
A copy of the presentation materials will be added to the “Publications” section of the Company’s website at tscan.com once presentations have concluded.
About TScan Therapeutics, Inc.
TScan is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to prevent relapse following allogeneic hematopoietic cell transplantation (the ALLOHATM Phase 1 heme trial). The Company is also developing TCR-T therapy candidates for the treatment of various solid tumors. The Company has developed and continues to expand its ImmunoBank, the Company’s repository of therapeutic TCRs that recognize diverse targets and are associated with multiple HLA types, to provide customized multiplex TCR-T therapies for patients with a variety of cancers.
Contacts
Heather Savelle
TScan Therapeutics, Inc.
VP, Investor Relations
857-399-9840
hsavelle@tscan.com
Maghan Meyers
Argot Partners
212-600-1902
TScan@argotpartners.com
FAQ
What is TScan Therapeutics presenting at the SITC 39th Annual Meeting?
When and where is the SITC 39th Annual Meeting taking place?
What is the focus of TScan Therapeutics' (TCRX) research?
How can investors access TScan Therapeutics' (TCRX) presentation materials from the SITC meeting?
